# Intracellular cytokine staining

Source: https://onco.cc/terms/intracellular-cytokine-staining/  
OnCo record `intracellular-cytokine-staining` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This test measures signaling proteins retained inside stimulated cells and identifies which stained cell groups produced them. The result describes a response in the assay.

## Summary

An original multiparameter flow-cytometry study detected intracellular cytokine accumulation after antigen stimulation and measured several cytokines in individual cells. That study concerned viral responses, not cancer-treatment prediction. The stimulated material, measured cytokines, cell groups and analysis gates define the result. Cytokine production is distinct from direct measurement of target-cell death, and assay validation does not by itself establish clinical benefit.

## Fields

- Kind: Term
- Last checked: 2026-11-10

## Notes

- Method card, what it measures: cytokines retained inside cells during a defined assay, so a response can be assigned to stained cell populations. How: cells get a defined stimulus, a protein-transport inhibitor is present for a stated window so newly made cytokines accumulate, the cells are fixed and made permeable, and flow cytometry reads cytokine stains beside population markers, with a viability stain applied before fixation. Input: viable blood or tissue cells, with separate aliquots per stimulus, and fixed cells cannot go on to living-cell assays. Output: percent cytokine-positive cells within a named parent population, or percent with stated cytokine combinations. Controls: unstimulated or vehicle, a positive stimulation, viability and recovery, single-stain and staining-boundary controls. It cannot tell natural tumour presentation, direct target-cell killing, receptor sequence identity or clinical benefit.
- Precision evidence: in a study among laboratories involved in HIV clinical trials, using a common protocol and a cytomegalovirus pp65 peptide mix, mean inter-laboratory coefficients of variation ranged from 17% to 44% depending on sample type and analysis method, cryopreserved PBMC gave lower variation than whole blood, and centralised analysis with a dynamic gating template cut it by 5% to 20%. Variation was lowest (18% to 24%) for samples with more than 0.5% interferon gamma positive T cells and highest (57% to 82%) for samples below 0.1%, so gating is a major source of variability and precision falls as the responding frequency falls (Maecker 2005). That study supports protocol and gating consistency and does not validate every panel, stimulus or disease.
- Fictional interpretation: a report finds cells positive for both interferon gamma and tumour necrosis factor after peptide stimulation. They are double-cytokine-positive under that assay and may not be called tumour-killing, because natural tumour recognition and death of appropriate targets need separate tests, and a strong response to a broad positive control confirms assay responsiveness and not recognition of the intended peptide. Polyfunctional means meeting the assay's rules for several measured functions, so it always needs its panel and stimulus attached, and a stained subset can contain many receptors.
- The stimulus changes the question. Added peptide can bypass some processing steps; whole protein needs suitable antigen-presenting cells and processing, while broad stimulation tests responsiveness without identifying the intended antigen. The 2021 flow-cytometry guidelines describe brefeldin A and monensin as transport inhibitors and explain that their choice and exposure window can affect what is measured. Intracellular accumulation after inhibition is not a measurement of how much cytokine reached the surrounding medium.
- Cytokine-positive percentages need a named parent gate, and fluorescence intensity uses instrument-dependent units. Poor recovery, handling delays, signal overlap, altered staining after fixation or permeabilisation, background and scarce events can make a small positive population unstable, and inhibitor timing belongs to the protocol. Minimum event counts, positivity boundaries and clinical interpretation need validation for the panel, stimulus and population; there is no universal double-positive percentage that proves tumour killing or treatment benefit.

## Sources

- Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency.: https://doi.org/10.1172/jci119338
- Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.: https://doi.org/10.1186/1471-2172-9-9
- Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.: https://doi.org/10.1016/s0022-1759(03)00265-5
- Standardization of cytokine flow cytometry assays.: https://doi.org/10.1186/1471-2172-6-13
- Standardization of cytokine flow cytometry assays.: https://pubmed.ncbi.nlm.nih.gov/15978127/
- Cossarizza et al.: flow cytometry and cell sorting guidelines, third edition (2021): https://doi.org/10.1002/eji.202170126

## Connected records

- terms: [ELISpot secretion assays](https://onco.cc/terms/elispot/), [Flow cytometry (immunophenotyping)](https://onco.cc/terms/flow-cytometry/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Immune-cell cytotoxicity assays](https://onco.cc/terms/immune-cytotoxicity-assays/), [Peptide-HLA multimer staining](https://onco.cc/terms/peptide-hla-multimer-staining/), [Peripheral blood mononuclear cell specimens](https://onco.cc/terms/pbmc-specimens/)

---
JSON: https://onco.cc/api/v1/entities/intracellular-cytokine-staining.json